Adnexus, a Bristol-Myers Squibb R&D Company, is a leader in the discovery and development of Adnectins, a proprietary type of targeted biologic.

Adnectins are proteins designed to either block or stimulate therapeutic targets of interest to help fight diseases across a broad range of therapeutic areas. Our proprietary technology for engineering these proteins creates an opportunity to rapidly generate compounds for study as potential treatment options for patients.

Contact Info

100 Beaver Street, Suite 300, Waltham, MA, 02453
Tel: (781) 891-3745

Polaris Lead

Amir Nashat